Leerink Partners assumed coverage on shares of Freenome (NASDAQ:FRNM – Get Free Report) in a report issued on Friday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $18.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 52.54% from the stock’s previous close.
Freenome Stock Up 1.6%
FRNM stock opened at $11.80 on Friday. The company has a market capitalization of $96.25 million, a P/E ratio of -196.67 and a beta of 0.35. Freenome has a 52 week low of $9.97 and a 52 week high of $14.26.
About Freenome
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.
Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.
Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.
Recommended Stories
- Five stocks we like better than Freenome
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
